Bifogade filer
Learning 2 Sleep completes the acquisition of the intestinal flora analysis company Symbio Me AB
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Vård & Omsorg |
Learning 2 Sleep L2S AB (publ) ("L2S") has completed the acquisition of Symbio Me AB ("Symbio Me" or "the Company") - a digital intestinal flora analysis company - which was announced on May 9, 2022. The purchase price of SEK 10 million has been paid through that the board of L2S has decided on the issue and allotment of 1,694,915 shares in L2S, which are issued at a price of approximately SEK 5.90 per share.
L2S has completed the acquisition of Symbio Me, which was announced on May 9, 2022. The company offers research-based intestinal flora analysis directly to consumers. The purchase price of SEK 10 million has been paid by the Board of L2S having decided on the issue and allotment of 1,694,915 shares in L2S to the sellers of the Company, who have paid full payment for the subscribed and allotted shares in the form of the shares in the Company.
In connection with the issue, L2S's share capital will be increased by approximately SEK 101,695 to approximately SEK 827,218 and the number of shares in L2S will increase from 12,092,058 to 13,786,973 shares in connection with the issue.